Citations

Clear

1575 citation(s) found for "Im, Gene".

Clinical significance of HFE gene mutations in patients with refractory anemia with ring sideroblasts (RARS).
Nanah, Rama , Patnaik, Mrinal M. , Gangat, Naseema , Zblewski, Darci, He, Rong , Nguyen, Phuong L., Elliott, Michelle A. , Litzow, Mark R. , Al‐Kali, Aref , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e18556-e18556

10.1200/jco.2017.35.15_suppl.e18556 Get It

e18556 Background: RARS is a subtype of myelodysplastic syndromes (MDS) defined by < 5% blasts and ≥15% ring sideroblasts (WHO 2008). Hereditary hemochromatosis is a disorder characterized by dysregulations in iron absorption, largely associated with C282Y and H63D mutations of the HFE gene. Iron levels are elevated in both disorders and pathophysiologic correlations were suggested. HFE gene mutations were previously found higher in MDS compared to controls (50% vs 36%) ( Nearman et al, Am J Hematol 2007). Methods: A total of 168 RARS patients’ data from 1994 to 2015 at Mayo Clinic were reviewed after appropriate IRB approval was obtained. All cases had their bone marrow slides reviewed at our center. We searched patients’ records retrospectively to Identify those tested for HFE gene (C282Y, H62D, S65C) mutations, done inside or outside our institution. Survival estimates were calculated using Kaplan-Meier curves. Results: Out of the 168 RARS patients, only 17 (10%) were tested for HFE gene mutations. Out of the 17 tested, 11 (65%) were found to have mutations; 2 of which (18%) had homozygous H63D mutation, 1 patient (9%) had double heterozygous H63D and C282Y mutations, 5 (45%) had only one H36D heterozygous mutation vs 3 patients (27%) with only one C282Y heterozygous mutation. Only one patient was tested for the additional S65C mutation and it was not detected. H63D mutation was present in a total of 8 patients (73%) vs C282Y mutation which was present in 4 patients (36%). Bone marrow iron stores were increased in all 17 tested patients, except one who had decreased stores, this patient had one heterozygous C282Y mutation. Median overall survival (mOS) was 117 months in the HFE mutated patients vs 75 months in the non-mutated (p = 0.6). Conclusions: Our study found the HFE gene, when tested, to be mutated in higher frequencies among patients with RARS compared to that reported in the general population (65% vs 36%), with H63D mutation in almost three quarters of all mutated patients. Although it did not reach statistical significance, the longer survival observed among HFE mutated patients compared to the wild-type raises the question whether testing for HFE gene mutations among patients with MDS-RARS should be further explored.
A study of thymidylate synthase gene expression as a biomarker for the treatment of esophageal adenocarcinoma.
Beamer, Staci E. , Gatalica, Zoran , Xiu, Joanne , Jaroszewski, Dawn E. , Stanton, Melissa, Pai, Rish K. , Krishna, Murli , Thomas, Mathew , Ross, Helen J. , Thomas, Mathew , Thomas, Mathew , Ho, Thai H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e15563-e15563

10.1200/jco.2017.35.15_suppl.e15563 Get It

e15563 Background: Expression of thymidylate synthase (TS), a target of fluoropyrimidine-based (5-FU) chemotherapy, has prognostic value in colorectal adenocarcinoma. Its value as a biomarker in treatment of esophageal adenocarcinoma (EAC) is unknown. With widespread adoption of CROSS trial protocol for treatment of EAC, 5-FU is frequently omitted from regimens. We retrospectively analyzed the association between TS protein expression and clinical outcomes in EAC. Methods: TS expression levels were measured by immunohistochemistry in formalin-fixed paraffin-embedded specimens from 35 primary EAC patients from 2 institutions (range 5/2006-1/2016); at time of diagnosis and surgical resection (33 neoadjuvant chemoradiation and 2 surgery alone). TS expression higher than 1+, 5% was read as positive. Mean follow up was 1323 days (range 263-3677). TS expression correlated with treatment response and survival in patients treated with and without 5-FU therapy (log-rank test, Kaplan-Meier method). Results: In the cohort of 35 patients, 21 patients (60%) had pretreatment positive TS expression. Overall survival (OS) for TS negative patients was 1216 days versus 974 days for TS positive (p = 0.15). In the 23 patients treated with 5-FU, TS-negative patients had a trend towards longer overall survival compared to TS-positive patients, mean OS (1272 days versus 743 days, p = 0.08). In the group of 12 patients not treated with 5-FU, 2 patients showed negative TS staining. Neoadjuvant chemoradiation was performed in 33/35 patients. Downstaging was observed in 69% (9/13) of patients with negative pre-treatment TS levels versus 55% (11/20) in pre-treatment TS positive patients (p = 0.48). In 23 patients treated with 5FU, 9/12 (75%) were downstaged in the TS-negative cohort versus 6/11 (45%) in the TS-positive cohort (p = 0.21). In the 5FU treatment group, complete response was seen in 2 patients with negative TS staining. Conclusions: Low TS expression in EAC patients trended towards improved survival and tumor downstaging, particularly in patients treated with neoadjuvant 5-FU and platinum based therapy. Prospective data and greater patient numbers may be necessary to demonstrate statistical significance.
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
Galon, Jérôme , Rossi, John M. , Turcan, Sarah, Danan, Corinne , Neelapu, Sattva S. , Bartlett, Nancy L. , Jacobson, Caron A. , Braunschweig, Ira , Oluwole, Olalekan O. , Timmerman, John M. , Lekakis, Lazaros J. , Unabia, Sherryonne, Go, William Y., Wiezorek, Jeffrey S., Bot, Adrian , Bartlett, Nancy L , Oluwole, Olalekan O , Galon, Jerome , Danan, Corinne, Locke, Frederick L. , Miklos, David B. , Siddiqi, Tanya , Lin, Yi , Reagan, Patrick Michael , Unabia, Sherry

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3025-3025

10.1200/jco.2017.35.15_suppl.3025 Get It

3025 Background: Axi-cel is an autologous anti-CD19 CAR T cell therapy. ZUMA-1 is a multicenter, registrational trial of axi-cel in patients (pts) with refractory/aggressive B-cell non-Hodgkin lymphoma (NHL). In a pre-specified interim analysis, ZUMA-1 met its primary endpoint with 76% objective response rate and 47% complete response (Blood 2016;128:LBA-6). We describe, for the first time, a tumor microenvironment immune gene signature associated with CAR T cell treatment (tx) of NHL pts. Methods: Paired biopsies, pre- and within 3 weeks post-axi-cel tx, were analyzed by digital gene expression followed by a pre-specified bioinformatics algorithm applied to IGES15 and IGES21 genes involved in immune-mediated tumor regression (Immunosign; Galon Immunity 2013). Immunosign profiles expression of a pre-defined set of effector T cell, Th1, chemokine, and cytokine genes. Expression analysis and hierarchical clustering were used to define an axi-cel-related tumor immune gene signature. Wilcoxon signed rank test with multiple test correction by FDR (Benjamini-Yekutieli) was used. Results: Gene expression profile comparisons of pre- and post-axi-cel tx biopsies from 14 pts showed profound changes in gene expression within the tumor environment after infusion. The most upregulated genes post-axi-cel tx were CCL5 (RANTES), CTLA4, and GZMA (log2 fold change > 2, P< 0.05, FDR < 0.050). Immune checkpoints PD-L1 and LAG3 were also upregulated post-axi-cel (log2 fold change > 1.6, P< 0.05, FDR < 0.055). Other genes associated with T cell proliferation, homing, and effector function were also upregulated: IL-15, GZMK, CXC3CL1 (Fractalkine), CD8A, and STAT4 (log2 fold change > 1.6; P< 0.05, FDR < 0.074). Additional baseline tumor characteristics and associative analysis will be presented. Conclusions: We define a mechanistic tumor immune gene signature in NHL pts associated with axi-cel tx. This signature comprises upregulation of T cell activation, effector, chemokine, and immune checkpoint genes. These data will potentially lead to rational optimization of T cell interventions in cancer Clinical trial information: NCT02348216.
Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).
Nowakowski, Grzegorz S. , Chiappella, Annalisa , Spina, Michele , Gascoyne, Randy D. , Zhang, Lei , Flament, Jocelyne, Repici, Jacqueline, Conlin, Erin, Delissio, Krista, Witzig, Thomas E. , Vitolo, Umberto

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7538-7538

10.1200/jco.2016.34.15_suppl.7538 Get It

Mutation analysis in metastatic colorectal cancers (mCRC) subjected to gene panel testing for BRAF and KRAS genes in clinical practice.
Foster, Nathan R. , Kipp, Benjamin R. , Voss, Jesse S. , Jones, Jeremy C , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15049-e15049

10.1200/jco.2016.34.15_suppl.e15049 Get It

Biomarkers of immune checkpoint inhibitor response in metastatic breast cancer: PD-L1 protein expression, CD274 gene amplification, and total mutational burden.
Gay, Laurie M. , Sheehan, Christine E., Dalvi, Siddhartha , Voronel, Olga, Elvin, Julia A. , Suh, James , Vergilio, Jo‐Anne, Fabrizio, David , Chumsri, Saranya , Ali, Siraj M. , Miller, Vincent A. , Stephens, Philip J., Ross, Jeffrey S , Elvin, Julia A , Frampton, Garrett M. , Chalmers, Zachary Rockow

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3057-3057

10.1200/jco.2016.34.15_suppl.3057 Get It

Risks of triple negative breast cancer associated with cancer predisposition gene mutations.
Akinhanmi, Margaret, Hallberg, Emily J., Moore, Raymond M. , LaDuca, Holly , Goldgar, David E. , Dolinsky, Jill S. , Couch, Fergus J. , Shimelis, Hermela , Hu, Chunling , Hart, Steven N. , Meeks, Huong , Huether, Robert , Chao, Elizabeth

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1513-1513

10.1200/jco.2016.34.15_suppl.1513 Get It

Association of CDKN2A gene alteration with high expression of PD-L1.
Azzouqa, A.G., Lou, Yanyan , Zhang, Yan , Marin‐Acevedo, Julian A. , Manochakian, Rami

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 9102-9102

10.1200/jco.2018.36.15_suppl.9102 Get It

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.
Siddiqui, Nauman , Purvey, Sneha , Hamal, Ruchi , Diasio, Robert B. , Saif, Wasif M., Zhang, Lulu

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2576-2576

10.1200/jco.2018.36.15_suppl.2576 Get It

Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).
Nowakowski, Grzegorz S. , Chiappella, Annalisa , Spina, Michele , Gascoyne, Randy D. , Russo, Jacqueline, Kang, Janet, Zhang, Jingshan , Xu, Yingyong, investigators, on behalf of the ROBUST study, Witzig, Thomas E. , Scott, David W. , Zhang, Lei , Vitolo, Umberto , investigators, on behalf of the ROBUST study

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7548-7548

10.1200/jco.2018.36.15_suppl.7548 Get It